Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

ZVRA PEER ANALYSIS

Zevra Therapeutics Inc. — metric-by-metric comparison with peers and the industry median

ZVRAZevra Therapeutics Inc.

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Biotechnology

Return Comparison

1-Year
Split-adjusted
ZVRA+43.4%MSB+27.6%TLX-28.2%RTALB+24.1%CSL-47.6%
Year-to-Date (YTD)
ZVRA+55.9%MSB-23.5%TLX+55.2%RTALB+5.0%CSL-27.1%
1-Year
Split-adjusted
ZVRA+43.4%SPRY-49.6%TBPH+52.5%CRMD-24.4%MRVI+121.0%FDMT+200.0%
Year-to-Date (YTD)
ZVRA+55.9%SPRY-28.5%TBPH-9.1%CRMD-24.4%MRVI+81.5%FDMT+69.6%

Key Metric Comparison

P/E

Lower is better
ZVRA—MSB—TLX—RTALB4.89CSL30.02Median 17.81

ROE

Higher is better
ZVRA—MSB-11.3%TLX-1.8%RTALB15.1%CSL7.7%Median -47.5%

Net Margin

Higher is better
ZVRA—MSB-115.3%TLX-0.9%RTALB136.3%CSL9.2%Median -125.7%

Revenue Growth

Higher is better
ZVRA—MSB410.4%TLX56.3%RTALB24.0%CSL4.8%Median 5.1%

P/E

Lower is better
ZVRA—SPRY—TBPH7.61CRMD4.52MRVI—FDMT—Median 17.81

ROE

Higher is better
ZVRA—SPRY-136.4%TBPH50.2%CRMD65.6%MRVI-40.8%FDMT-34.9%Median -47.5%

Net Margin

Higher is better
ZVRA—SPRY-200.0%TBPH104.3%CRMD45.2%MRVI-51.1%FDMT-182.3%Median -125.7%

Revenue Growth

Higher is better
ZVRA—SPRY1.9%TBPH68.2%CRMD384.6%MRVI-15.4%FDMT383,560.9%Median 5.1%

All Metrics

Valuation
MetricZVRAMSBTLXRTALBCSLInd. Median
P/E———4.89●30.0217.81
P/B4.09—6.560.61●2.243.49
EV/EBITDA——123.3174.6110.37●14.92
P/S—31.913.346.672.67●10.89
Financial Health
MetricZVRAMSBTLXRTALBCSLInd. Median
Current Ratio4.89●—1.431.212.575.90
Debt/Equity0.6%●—112.3%1.2%67.4%10.9%
NetDebt/EBITDA——13.130.90●2.221.15
Profitability
MetricZVRAMSBTLXRTALBCSLInd. Median
Net Margin—-115.3%-0.9%136.3%●9.2%-125.7%
ROE—-11.3%-1.8%15.1%●7.7%-47.5%
ROA—-8.6%-0.7%13.1%●3.8%-35.8%
EBITDA Margin—-76.6%3.0%9.0%32.8%●-105.8%
Growth + Dividend
MetricZVRAMSBTLXRTALBCSLInd. Median
Rev. Growth—410.4%●56.3%24.0%4.8%5.1%
NI Growth———134.0%●-39.4%12.1%
Div. Yield—0.0%—0.0%2.5%●0.2%
Payout—0.0%—0.0%103.1%0.0%
Valuation
MetricZVRASPRYTBPHCRMDMRVIFDMTInd. Median
P/E——7.614.52●——17.81
P/B4.0913.493.001.87●4.081.923.49
EV/EBITDA——3.863.69●——14.92
P/S—8.367.942.04●4.229.8110.89
Financial Health
MetricZVRASPRYTBPHCRMDMRVIFDMTInd. Median
Current Ratio4.894.9413.14●2.985.919.345.90
Debt/Equity0.6%●157.4%25.2%33.2%128.0%4.5%10.9%
NetDebt/EBITDA—0.54-2.26●-0.16-1.012.271.15
Profitability
MetricZVRASPRYTBPHCRMDMRVIFDMTInd. Median
Net Margin—-200.0%104.3%●45.2%-51.1%-182.3%-125.7%
ROE—-136.4%50.2%65.6%●-40.8%-34.9%-47.5%
ROA—-64.4%28.1%37.5%●-12.5%-31.3%-35.8%
EBITDA Margin—-194.1%129.8%●53.2%-50.8%-185.2%-105.8%
Growth + Dividend
MetricZVRASPRYTBPHCRMDMRVIFDMTInd. Median
Rev. Growth—1.9%68.2%384.6%-15.4%383,560.9%●5.1%
NI Growth———953.6%——12.1%
Div. Yield——————0.2%
Payout——————0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ZVRA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.